{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:45:01Z","timestamp":1790610301866,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1118,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["R01 DE 019727"],"award-info":[{"award-number":["R01 DE 019727"]}]},{"name":"National Institute of Health","award":["P50 CA097190"],"award-info":[{"award-number":["P50 CA097190"]}]},{"name":"National Institute of Health","award":["T32 CA060397"],"award-info":[{"award-number":["T32 CA060397"]}]},{"DOI":"10.13039\/100008603","name":"University of Pittsburgh Cancer Institute","doi-asserted-by":"crossref","award":["P30 CA047904"],"award-info":[{"award-number":["P30 CA047904"]}],"id":[{"id":"10.13039\/100008603","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1093\/annonc\/mdw428","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T03:05:53Z","timestamp":1475636753000},"page":"2257-2262","source":"Crossref","is-referenced-by-count":33,"title":["Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"R.L.","family":"Ferris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Duvvuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Clump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Ohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.E.","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Argiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1093\/annonc\/mdw428_bb0010","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdw428_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1093\/annonc\/mdw428_bb0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdw428_bb0025","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"issue":"43","key":"10.1093\/annonc\/mdw428_bb0030","doi-asserted-by":"crossref","first-page":"15599","DOI":"10.1073\/pnas.0409730102","article-title":"Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis","volume":"102","author":"Goessel","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"10.1093\/annonc\/mdw428_bb0035","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res"},{"issue":"11","key":"10.1093\/annonc\/mdw428_bb0040","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Rubin Grandis","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1093\/annonc\/mdw428_bb0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1093\/annonc\/mdw428_bb0050","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1093\/annonc\/mdw428_bb0055","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2013.53.9163","article-title":"Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234","volume":"32","author":"Harari","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdw428_bb0060","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/1078-0432.CCR-07-1509","article-title":"Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies","volume":"14","author":"Weiner","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1093\/annonc\/mdw428_bb0065","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"10.1093\/annonc\/mdw428_bb0070","doi-asserted-by":"crossref","unstructured":"Mes\u00eda R, Henke M, Fortin A et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):208\u2013220.","DOI":"10.1016\/S1470-2045(14)71198-2"},{"issue":"27","key":"10.1093\/annonc\/mdw428_bb0075","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdw428_bb0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw428_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14712598.6.3.231","article-title":"STAT3 as a therapeutic target in head and neck cancer","volume":"6","author":"Leeman","year":"2006","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"10.1093\/annonc\/mdw428_bb0090","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1523\/JNEUROSCI.5842-08.2009","article-title":"Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate","volume":"29","author":"Schmitt","year":"2009","journal-title":"J Neurosci"},{"issue":"7","key":"10.1093\/annonc\/mdw428_bb0095","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1074\/jbc.M302637200","article-title":"STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis","volume":"279","author":"Townsend","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1093\/annonc\/mdw428_bb0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cncr.22813","article-title":"STAT1 activation in squamous cell cancer of the oral cavity: a potential predictive marker of response to adjuvant chemotherapy","volume":"110","author":"Laimer","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdw428_bb0105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/2326-6066.CIR-15-0053","article-title":"STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients","volume":"3","author":"Srivastava","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1093\/annonc\/mdw428_bb0110","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1158\/1535-7163.MCT-15-0305","article-title":"STAT1 activation is enhanced by cisplatin and variably affected by EGFR inhibition in HNSCC cells","volume":"14","author":"Schmitt","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/12\/2257\/8623093\/mdw428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:01:49Z","timestamp":1624698109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0923753419365512"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw428","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}